Induction of abortion by prostaglandins in the second trimester of pregnancy. A review.
D000020:Abortifacient Agents, Nonsteroidal; D000028:Abortion, Induced / Q000009:adverse effects / Q000379:methods* / Q000592:standards; D000650:Amnion; D002260:Carboprost / Q000009:adverse effects; D002318:Cardiovascular Diseases / Q000139:chemically induced; D002584:Cervix Uteri / Q000293:injuries; D015237:Dinoprost; D015232:Dinoprostone / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D007267:Injections; D007273:Injections, Intramuscular; D010121:Oxytocin / Q000009:adverse effects; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D011453:Prostaglandins / Q000008:administration & dosage / Q000009:adverse effects; D011459:Prostaglandins E, Synthetic / Q000009:adverse effects; D011460:Prostaglandins F / Q000009:adverse effects; D013488:Suppositories; D014599:Uterus; D014621:Vagina
D000020:Abortifacient Agents, Nonsteroidal; D011453:Prostaglandins; D011459:Prostaglandins E, Synthetic; D011460:Prostaglandins F; D013488:Suppositories; D010121:Oxytocin; C016767:sulprostone; D002260:Carboprost; D015237:Dinoprost; D015232:Dinoprostone